RBC Capital Lifts PT on Incyte Corporation (INCY) to $95 From $92

Incyte Corporation (NASDAQ:INCY) is one of the most undervalued biotech stocks to buy right now. RBC Capital raised the price target on Incyte Corporation (NASDAQ:INCY) to $95 from $92 on April 7, reiterating a Sector Perform rating on the shares. The rating update came as part of a broader research note previewing the fiscal Q1 results in the Biotech sector, with the firm telling investors in the research note that factors such as seasonal headwinds around gross/net, reimbursement resets, and fewer selling days may be exacerbated in fiscal Q1 by weather impact. This holds especially true for launching and in-clinic products. However, RBC Capital added that the robust return of M&A, along with clarity on limited tariff/Most Favored Nation drug pricing impacts, may prove helpful in offsetting both this and broader macro volatility while keeping sector perceptions favorable.

Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds is Buying

For additional perspective, in its financial results for fiscal Q4 and the full year ended December 31, 2025, Incyte Corporation reported a total revenue of $1.51 billion for the quarter, up 28% compared to the prior year period. Management attributed the growth to an increase in total net product revenue and milestone and contract revenue. Total revenue for the full year reached $5.14 billion, reflecting a growth of 21% compared to the prior year period and primarily driven by growth in the total net product revenue and milestone and contract revenue.

Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics, focusing on oncology, hematology, inflammation, and autoimmunity therapeutic areas.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Follow Insider Monkey on Google News.